Daniel Ledesma is a litigation associate in the Intellectual Property practice within the Firm's Competition Group. His practice focuses on intellectual property litigation, in addition to commercial litigation and antitrust matters. Daniel's work also includes transactions and advisory matters involving the licensing, development, and acquisition of intellectual property and information technology. Daniel works with clients in a variety of sectors, including consumer products, pharmaceuticals, media, manufacturing, and technology.
Counsel to Pfizer in inter partes review proceedings concerning vaccine patents.
Counsel to Pfizer in a Federal Circuit appeal from an inter partes review proceeding concerning protein-purification patents.
Counsel to a leading global pharmaceutical company in a litigation arising from the Biologics Price Competition and Innovation Act relating to its biosimilar product.
Counsel to Allergan in a nationwide antitrust class action lawsuit arising from Sherman Act claims regarding an exclusive license agreement relating to Botox® Cosmetic.
Counsel to Warner Chilcott in defending against claims of monopolization based on alleged "product hopping" in connection with Doryx®.
Counsel to Pfizer in antitrust litigations concerning the drugs Lipitor®
Counsel to Avon Rubber p.l.c. on its strategic acquisition of 3M's ballistic-protection business in the United States.